A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. - Wikidata - awgldk - TriplyDB

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33410997

about

Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Panobinostat for the treatment of multiple myeloma: the evidence to date Innovative agents in multiple myeloma Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2.Dinutuximab and Panobinostat Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat Targeting EZH2 for cancer therapy: progress and perspective.Panobinostat: a review of trial results and future prospects in multiple myeloma.Panobinostat: first global approval.Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.Therapeutic applications of histone deacetylase inhibitors in sarcoma.Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma.

P2860

Q26771601-71A5D554-45AC-4A7B-93A6-C91E3E159EC7 Q26778674-94667A97-B4CA-4C27-9B6D-3FEF0F20A121 Q27022493-592513F4-F0C9-4C6C-BED1-136D351FF37E Q28082536-6D970F7E-B215-422F-B920-C2C9379E9611 Q30802505-2075FB5D-3A3D-435C-8792-2CABD314D502 Q33432845-BA618B24-FAC6-4F7C-A168-C68F88D4A42D Q34602263-DF8E3953-78C2-4B4A-8F5D-7D4C46D43FF4 Q35592352-B903571D-9693-4E5E-9BA0-7EECC6C53F91 Q36572408-CB8F4D46-8E59-4A05-AC25-CC5ED0A2B8A4 Q37199772-5D70FD8F-0E3C-482E-B89E-CA4E310103FB Q37204063-E5C5CE36-3065-4DE4-9BA3-6DC6DB1A107D Q38269612-A14BD346-4593-4EC7-8CC3-F1513FDB13E8 Q38403118-A90EF276-640A-4845-AB56-BDF92D94B80B Q38716460-1BD21A8F-2E43-4665-BEFA-DB64CD958321 Q39450827-4678CA39-18D6-4262-8F92-7C7C406D023A Q41088379-41E569EF-18EF-4F26-99FA-A371BB7603DA Q41645533-2FF2AE47-C417-4757-9F47-3C27E757E02B Q42425704-993EA8D6-ACF3-4918-87CC-DCF192F4FDD8 Q50166078-194FBCEF-9F61-4C80-B980-F42C24E10BFF

P2860

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33410997

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A phase 1/2 study of oral pano ...... r refractory multiple myeloma.

@ast

A phase 1/2 study of oral pano ...... r refractory multiple myeloma.

@en

type

label

A phase 1/2 study of oral pano ...... r refractory multiple myeloma.

@ast

A phase 1/2 study of oral pano ...... r refractory multiple myeloma.

@en

prefLabel

A phase 1/2 study of oral pano ...... r refractory multiple myeloma.

@ast

A phase 1/2 study of oral pano ...... r refractory multiple myeloma.

@en

P1433

Q33410997-012DB83F-79FF-421A-9AC4-554521A6EF96

P1476

Q33410997-CB271D04-1C27-4CCE-BB40-A7228D638BA1

P2093

Q33410997-23705A50-C052-4BD3-AFF8-F12E33ED1CB1

Q33410997-3524A66D-2A2D-41FE-A902-7EAFCEBAC223

Q33410997-3B312A66-86D1-4FED-8C65-48F00F5C7A96

Q33410997-44FF6C78-93C0-4714-A181-A5AC0CBCA69E

Q33410997-48EE794B-A133-47DC-A583-2D57102D935C

Q33410997-628C1D6E-AEB4-443B-ADCD-7A4CA3F80325

Q33410997-62C8B588-60AE-4F56-9D1C-151AEC36FBFB

Q33410997-72048B7A-D772-4B44-8884-9C3AD362FE02

Q33410997-7E442FE5-B010-4BDA-B8A5-E7D25D427094

Q33410997-A55FCC11-74B4-4AB5-ACDD-0186CC751870

P2860

Q33410997-09CB0AD1-8434-4848-A8D9-6D748AFD0EDD

Q33410997-09E5D03B-D9F3-45FF-98FE-5FF6BD43C16D

Q33410997-13B748FB-411C-4B4A-929C-1932F3540B28

Q33410997-13D11BE5-9F6C-4506-9CD0-5B8965E11571

Q33410997-1A5E3A32-D179-4611-B64F-4AE01C36B1B8

Q33410997-1C7119E4-39BD-4B3E-8DA6-CE1FB89F0FD8

Q33410997-3F570D5B-985D-49FC-B70F-D40762713043

Q33410997-46F746BC-B23C-4F34-9171-7E4D3BDD91E9

Q33410997-4D8E4654-8CB7-4B8B-ADEB-F9AF3E7B90E4

Q33410997-52FEC6F2-90F4-4E0F-A307-68D8616364CF

P304

Q33410997-10D66384-6BB9-4AFC-973D-77E0260AB3B5

P31

Q33410997-EAA88A43-E985-45D5-9B09-5CD41189BE03

P356

Q33410997-B15884CD-66D7-4CF2-985E-E6235606686C

P433

Q33410997-F4E5AFB1-3B74-4CD1-B7FD-61EE83F73E66

P478

Q33410997-BE78A3B9-386A-4441-81F0-4552A89CF9A5

P577

Q33410997-D1CBF89D-B590-480D-A0C5-509D2223F54E

P698

Q33410997-DF39215D-FB47-4D52-8747-082C3A6D48F6

P356

S00277-013-1910-2

P1433

Annals of Hematology

P1476

A phase 1/2 study of oral pano ...... r refractory multiple myeloma.

@en

P2093

Edwin C Kingsley

http://www.w3.org/2001/XMLSchema#string

Hassan H Ghazal

http://www.w3.org/2001/XMLSchema#string

James D Hilger

http://www.w3.org/2001/XMLSchema#string

James R Berenson

http://www.w3.org/2001/XMLSchema#string

Jeffrey Matous

http://www.w3.org/2001/XMLSchema#string

Kenneth Dressler

http://www.w3.org/2001/XMLSchema#string

Ori Yellin

http://www.w3.org/2001/XMLSchema#string

Ralph V Boccia

http://www.w3.org/2001/XMLSchema#string

Regina A Swift

http://www.w3.org/2001/XMLSchema#string

Robert Vescio

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.

Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

P304

89-98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-013-1910-2

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24135804

http://www.w3.org/2001/XMLSchema#string